{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T17:33:23Z","timestamp":1763141603459,"version":"build-2065373602"},"reference-count":66,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T00:00:00Z","timestamp":1625443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Hypertrophic cardiomyopathy (HCM) is the most common monogenic cardiac disease with a highly variable phenotypic expression, ranging from asymptomatic to drug refractory heart failure (HF) presentation. Pharmacological therapy is the first line of treatment, but options are currently limited to nonspecific medication like betablockers or calcium channel inhibitors, with frequent suboptimal results. While being the gold standard practice for the management of drug refractory HCM patients, septal reduction therapy (SRT) remains an invasive procedure with associated surgical risks and it requires the expertise of the operating centre, thus limiting its accessibility. It is therefore with high interest that researchers look for pharmacological alternatives that could provide higher rates of success. With new data gathering these past years as well as the development of a new drug class showing promising results, this review provides an up-to-date focused synthesis of existing medical treatment options and future directions for HCM pharmacological treatment.<\/jats:p>","DOI":"10.3390\/ijms22137218","type":"journal-article","created":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T22:02:04Z","timestamp":1625522524000},"page":"7218","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Pushing the Limits of Medical Management in HCM: A Review of Current Pharmacological Therapy Options"],"prefix":"10.3390","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6439-4561","authenticated-orcid":false,"given":"Cristian","family":"St\u0103tescu","sequence":"first","affiliation":[{"name":"Cardiology Department, Cardiovascular Diseases Institute \u201cProf. Dr. George I.M. Georgescu\u201d, Carol I Boulevard No. 50, 700503 Ia\u0219i, Romania"},{"name":"Internal Medicine Department, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7282-4904","authenticated-orcid":false,"given":"\u0218tefana","family":"Enachi","sequence":"additional","affiliation":[{"name":"Cardiology Department, Cardiovascular Diseases Institute \u201cProf. Dr. George I.M. Georgescu\u201d, Carol I Boulevard No. 50, 700503 Ia\u0219i, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1495-5062","authenticated-orcid":false,"given":"Carina","family":"Ureche","sequence":"additional","affiliation":[{"name":"Cardiology Department, Cardiovascular Diseases Institute \u201cProf. Dr. George I.M. Georgescu\u201d, Carol I Boulevard No. 50, 700503 Ia\u0219i, Romania"},{"name":"Internal Medicine Department, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1547-3620","authenticated-orcid":false,"given":"Laura","family":"\u021a\u0103poi","sequence":"additional","affiliation":[{"name":"Cardiology Department, Cardiovascular Diseases Institute \u201cProf. Dr. George I.M. Georgescu\u201d, Carol I Boulevard No. 50, 700503 Ia\u0219i, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larisa","family":"Anghel","sequence":"additional","affiliation":[{"name":"Cardiology Department, Cardiovascular Diseases Institute \u201cProf. Dr. George I.M. Georgescu\u201d, Carol I Boulevard No. 50, 700503 Ia\u0219i, Romania"},{"name":"Internal Medicine Department, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delia","family":"\u0218alaru","sequence":"additional","affiliation":[{"name":"Cardiology Department, Cardiovascular Diseases Institute \u201cProf. Dr. George I.M. Georgescu\u201d, Carol I Boulevard No. 50, 700503 Ia\u0219i, Romania"},{"name":"Internal Medicine Department, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Ple\u0219oianu","sequence":"additional","affiliation":[{"name":"Cardiology Department, Cardiovascular Diseases Institute \u201cProf. Dr. George I.M. Georgescu\u201d, Carol I Boulevard No. 50, 700503 Ia\u0219i, Romania"},{"name":"Internal Medicine Department, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7843-9668","authenticated-orcid":false,"given":"M\u0103d\u0103lina","family":"Bostan","sequence":"additional","affiliation":[{"name":"Cardiology Department, Cardiovascular Diseases Institute \u201cProf. Dr. George I.M. Georgescu\u201d, Carol I Boulevard No. 50, 700503 Ia\u0219i, Romania"},{"name":"Internal Medicine Department, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Drago\u0219","family":"Marcu","sequence":"additional","affiliation":[{"name":"Cardiology Department, Cardiovascular Diseases Institute \u201cProf. Dr. George I.M. Georgescu\u201d, Carol I Boulevard No. 50, 700503 Ia\u0219i, Romania"},{"name":"Internal Medicine Department, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mircea","family":"Ovanez Balasanian","sequence":"additional","affiliation":[{"name":"Cardiology Department, Cardiovascular Diseases Institute \u201cProf. Dr. George I.M. Georgescu\u201d, Carol I Boulevard No. 50, 700503 Ia\u0219i, Romania"},{"name":"Internal Medicine Department, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radu Andy","family":"Sasc\u0103u","sequence":"additional","affiliation":[{"name":"Cardiology Department, Cardiovascular Diseases Institute \u201cProf. Dr. George I.M. Georgescu\u201d, Carol I Boulevard No. 50, 700503 Ia\u0219i, Romania"},{"name":"Internal Medicine Department, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,7,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1161\/CIRCRESAHA.117.311059","article-title":"Hypertrophic Cardiomyopathy","volume":"121","author":"Marian","year":"2017","journal-title":"Circ. Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1056\/NEJMra1710575","article-title":"Clinical Course and Management of Hypertrophic Cardiomyopathy","volume":"379","author":"Maron","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1161\/01.CIR.0000066323.15244.54","article-title":"Hypertrophic Cardiomyopathy","volume":"107","author":"Richard","year":"2003","journal-title":"Circulation"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.mayocp.2014.01.025","article-title":"Characterization of a Phenotype-Based Genetic Test Prediction Score for Unrelated Patients With Hypertrophic Cardiomyopathy","volume":"89","author":"Bos","year":"2014","journal-title":"Mayo Clin. Proc."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jchf.2018.02.010","article-title":"Hypertrophic Cardiomyopathy","volume":"6","author":"Geske","year":"2018","journal-title":"JACC Heart Fail."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.117.033200","article-title":"Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy","volume":"138","author":"Ho","year":"2018","journal-title":"Circulation"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC)","volume":"35","author":"Elliott","year":"2014","journal-title":"Eur. Heart J."},{"key":"ref_8","first-page":"558","article-title":"2020 AHA\/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy","volume":"142","author":"Ommen","year":"2020","journal-title":"Circulation"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e235","DOI":"10.1016\/j.amjmed.2017.12.031","article-title":"Clinical Profile of Nonresponders to Surgical Myectomy with Obstructive Hypertrophic Cardiomyopathy","volume":"131","author":"Wells","year":"2018","journal-title":"Am. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1093\/eurheartj\/ehs150","article-title":"Pharmacological treatment options for hypertrophic cardiomyopathy: High time for evidence","volume":"33","author":"Spoladore","year":"2012","journal-title":"Eur. Heart J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.amjmed.2018.02.025","article-title":"Effect of Spironolactone on Myocardial Fibrosis and Other Clinical Variables in Patients with Hypertrophic Cardiomyopathy","volume":"131","author":"Maron","year":"2018","journal-title":"Am. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0140-6736(99)06187-5","article-title":"Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy","volume":"355","author":"Marian","year":"2000","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1161\/01.CIR.103.6.789","article-title":"Angiotensin II Blockade Reverses Myocardial Fibrosis in a Transgenic Mouse Model of Human Hypertrophic Cardiomyopathy","volume":"103","author":"Lim","year":"2001","journal-title":"Circulation"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.jchf.2013.09.001","article-title":"Effects of Losartan on Left Ventricular Hypertrophy and Fibrosis in Patients With Nonobstructive Hypertrophic Cardiomyopathy","volume":"1","author":"Shimada","year":"2013","journal-title":"JACC Heart Fail."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S2213-8587(14)70241-4","article-title":"Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: The INHERIT randomised, double-blind, placebo-controlled trial","volume":"3","author":"Axelsson","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/heartjnl-2015-308343","article-title":"Functional effects of losartan in hypertrophic cardiomyopathy\u2014A randomised clinical trial","volume":"102","author":"Axelsson","year":"2016","journal-title":"Heart"},{"key":"ref_17","first-page":"006231","article-title":"Baseline Characteristics of the VANISH Cohort","volume":"12","author":"Raja","year":"2019","journal-title":"Circ. Heart Fail."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.112.134932","article-title":"Late Sodium Current Inhibition Reverses Electromechanical Dysfunction in Human Hypertrophic Cardiomyopathy","volume":"127","author":"Coppini","year":"2013","journal-title":"Circulation"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"003565","DOI":"10.1161\/CIRCHEARTFAILURE.116.003565","article-title":"Ranolazine Prevents Phenotype Development in a Mouse Model of Hypertrophic Cardiomyopathy","volume":"10","author":"Coppini","year":"2017","journal-title":"Circ. Heart Fail."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e004124","DOI":"10.1161\/CIRCHEARTFAILURE.117.004124","article-title":"Efficacy of Ranolazine in Patients With Symptomatic Hypertrophic Cardiomyopathy","volume":"11","author":"Olivotto","year":"2018","journal-title":"Circ. Heart Fail."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e002764","DOI":"10.1161\/CIRCHEARTFAILURE.115.002764","article-title":"Novel Approach Targeting the Complex Pathophysiology of Hypertrophic Cardiomyopathy","volume":"9","author":"Olivotto","year":"2016","journal-title":"Circ. Heart Fail."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1016\/S0735-1097(02)03009-7","article-title":"Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy","volume":"41","author":"Crilley","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1039\/C4MB00594E","article-title":"Changes in the cardiac metabolome caused by perhexiline treatment in a mouse model of hypertrophic cardiomyopathy","volume":"11","author":"Gehmlich","year":"2014","journal-title":"Mol. BioSyst."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1161\/CIRCULATIONAHA.109.934059","article-title":"Metabolic Modulator Perhexiline Corrects Energy Deficiency and Improves Exercise Capacity in Symptomatic Hypertrophic Cardiomyopathy","volume":"122","author":"Abozguia","year":"2010","journal-title":"Circulation"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1001\/jamacardio.2018.4847","article-title":"Effect of Trimetazidine Dihydrochloride Therapy on Exercise Capacity in Patients With Nonobstructive Hypertrophic Cardiomyopathy","volume":"4","author":"Coats","year":"2019","journal-title":"JAMA Cardiol."},{"key":"ref_26","first-page":"3893","article-title":"Myofilament Ca2+ sensitization causes susceptibility to cardiac arrhythmia in mice","volume":"118","author":"Baudenbacher","year":"2008","journal-title":"J. Clin. Investig."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1161\/CIRCGENETICS.113.000324","article-title":"Desensitization of myofilaments to Ca2+ as a therapeutic target for hypertrophic cardiomyopathy with mutations in thin filament proteins","volume":"7","author":"Alves","year":"2014","journal-title":"Circ. Cardiovasc. Genet."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1111\/j.1476-5381.2010.00942.x","article-title":"Biological actions of green tea catechins on cardiac troponin C","volume":"161","author":"Tadano","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1161\/CIRCGENETICS.115.001234","article-title":"Green Tea Catechin Normalizes the Enhanced Ca2+ Sensitivity of Myofilaments Regulated by a Hypertrophic Cardiomyopathy\u2013Associated Mutation in Human Cardiac Troponin I (K206I)","volume":"8","author":"Warren","year":"2015","journal-title":"Circ. Cardiovasc. Genet."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"607","DOI":"10.3389\/fphys.2016.00607","article-title":"Epigallocatechin-3-Gallate Accelerates Relaxation and Ca2+ Transient Decay and Desensitizes Myofilaments in Healthy and Mybpc3-Targeted Knock-in Cardiomyopathic Mice","volume":"7","author":"Friedrich","year":"2016","journal-title":"Front. Physiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/00005344-200007000-00017","article-title":"Impact of \u03b2-Adrenoceptor Antagonists on Myofilament Calcium Sensitivity of Rabbit and Human Myocardium","volume":"36","author":"Zeitz","year":"2000","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3389\/fphys.2017.00558","article-title":"Nebivolol Desensitizes Myofilaments of a Hypertrophic Cardiomyopathy Mouse Model","volume":"8","author":"Kresin","year":"2017","journal-title":"Front. Physiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jacc.2005.10.041","article-title":"Antifibrotic Effects of Antioxidant N-Acetylcysteine in a Mouse Model of Human Hypertrophic Cardiomyopathy Mutation","volume":"47","author":"Marian","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1161\/CIRCULATIONAHA.108.790501","article-title":"Resolution of Established Cardiac Hypertrophy and Fibrosis and Prevention of Systolic Dysfunction in a Transgenic Rabbit Model of Human Cardiomyopathy Through Thiol-Sensitive Mechanisms","volume":"119","author":"Lombardi","year":"2009","journal-title":"Circulation"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"H1720","DOI":"10.1152\/ajpheart.00339.2015","article-title":"N-acetylcysteine reverses diastolic dysfunction and hypertrophy in familial hypertrophic cardiomyopathy","volume":"309","author":"Wilder","year":"2015","journal-title":"Am. J. Physiol. Circ. Physiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1161\/CIRCRESAHA.117.312647","article-title":"Hypertrophy Regression With N-Acetylcysteine in Hypertrophic Cardiomyopathy (HALT-HCM)","volume":"122","author":"Marian","year":"2018","journal-title":"Circ. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/0006-3002(55)90040-8","article-title":"A powerful reactivator of alkylphosphate-inhibited acetylcholinesterase","volume":"18","author":"Wilson","year":"1955","journal-title":"Biochim. Biophys. Acta Bioenerg."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0167-4889(00)00005-7","article-title":"Myosins: A diverse superfamily","volume":"1496","author":"Sellers","year":"2000","journal-title":"Biochim. Biophys. Acta Bioenerg."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1146\/annurev.biophys.050708.133751","article-title":"Structural and Functional Insights into the Myosin Motor Mechanism","volume":"39","author":"Sweeney","year":"2010","journal-title":"Annu. Rev. Biophys."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/ncb734","article-title":"A small-molecule inhibitor of skeletal muscle myosin II","volume":"4","author":"Cheung","year":"2001","journal-title":"Nat. Cell Biol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"14832","DOI":"10.1021\/bi0490284","article-title":"Kinetic Mechanism of Blebbistatin Inhibition of Nonmuscle Myosin IIB","volume":"43","author":"Ramamurthy","year":"2004","journal-title":"Biochem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"35557","DOI":"10.1074\/jbc.M405319200","article-title":"Mechanism of Blebbistatin Inhibition of Myosin II","volume":"279","author":"Sellers","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nsmb908","article-title":"The structural basis of blebbistatin inhibition and specificity for myosin II","volume":"12","author":"Allingham","year":"2005","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1126\/science.1081412","article-title":"Dissecting Temporal and Spatial Control of Cytokinesis with a Myosin II Inhibitor","volume":"299","author":"Straight","year":"2003","journal-title":"Science"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s10974-004-6060-7","article-title":"Specificity of blebbistatin, an inhibitor of myosin II","volume":"25","author":"Limouze","year":"2004","journal-title":"J. Muscle Res. Cell Motil."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"9410","DOI":"10.1021\/acs.jmedchem.8b00503","article-title":"Medicinal Chemistry and Use of Myosin II Inhibitor (S)-Blebbistatin and Its Derivatives","volume":"61","author":"Roman","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1126\/science.aad3456","article-title":"A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice","volume":"351","author":"Green","year":"2016","journal-title":"Science"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"16571","DOI":"10.1074\/jbc.M117.776815","article-title":"A small-molecule modulator of cardiac myosin acts on multiple stages of the myosin chemomechanical cycle","volume":"292","author":"Kawas","year":"2017","journal-title":"J. Biol. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1161\/01.CIR.0000019070.70491.6D","article-title":"Assessment of Diastolic Function With Doppler Tissue Imaging to Predict Genotype in Preclinical Hypertrophic Cardiomyopathy","volume":"105","author":"Ho","year":"2002","journal-title":"Circulation"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.echo.2013.10.012","article-title":"Early Changes in Apical Rotation in Genotype Positive Children with Hypertrophic Cardiomyopathy Mutations without Hypertrophic Changes on Two-Dimensional Imaging","volume":"27","author":"Forsey","year":"2014","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1532-429X-13-3","article-title":"Increased left ventricular torsion in hypertrophic cardiomyopathy mutation carriers with normal wall thickness","volume":"13","author":"Brouwer","year":"2011","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Stern, J.A., Markova, S., Ueda, Y., Kim, J.B., Pascoe, P., Evanchik, M.J., Green, E.M., and Harris, S.P. (2016). A Small Molecule Inhibitor of Sarcomere Contractility Acutely Relieves Left Ventricular Outflow Tract Obstruction in Feline Hypertrophic Cardiomyopathy. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0168407"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"741","DOI":"10.7326\/M18-3016","article-title":"Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy","volume":"170","author":"Heitner","year":"2019","journal-title":"Ann. Intern. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e006853","DOI":"10.1161\/CIRCHEARTFAILURE.120.006853","article-title":"Study Design and Rationale of EXPLORER-HCM","volume":"13","author":"Ho","year":"2020","journal-title":"Circ. Heart Fail."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1177\/2047487319898106","article-title":"Predictors of exercise capacity following septal myectomy in patients with hypertrophic cardiomyopathy","volume":"27","author":"Smith","year":"2020","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1161\/CIRCULATIONAHA.120.052359","article-title":"Mavacamten Favorably Impacts Cardiac Structure in Obstructive Hypertrophic Cardiomyopathy","volume":"143","author":"Saberi","year":"2021","journal-title":"Circulation"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1016\/j.jacc.2013.04.004","article-title":"B-Type Natriuretic Peptide and Survival in Hypertrophic Cardiomyopathy","volume":"61","author":"Geske","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/1206217","article-title":"Review of Echocardiographic Findings in Patients with Obstructive Sleep Apnea","volume":"2018","author":"Zota","year":"2018","journal-title":"Can. Respir. J."},{"key":"ref_60","first-page":"A20593","article-title":"Abstract 20593: In vivo Cardiac Effects of Mavacamten (MYK-461): Evidence for Negative Inotropy and Improved Compliance","volume":"136","author":"Ueyama","year":"2017","journal-title":"Circulation"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"E8143","DOI":"10.1073\/pnas.1809540115","article-title":"Deciphering the super relaxed state of human \u03b2-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers","volume":"115","author":"Anderson","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1016\/j.jacc.2020.03.064","article-title":"Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy","volume":"75","author":"Ho","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.amjcard.2013.04.060","article-title":"Usefulness of High-Sensitivity Cardiac Troponin T and Brain Natriuretic Peptide as Biomarkers of Myocardial Fibrosis in Patients with Hypertrophic Cardiomyopathy","volume":"112","author":"Kawasaki","year":"2013","journal-title":"Am. J. Cardiol."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Bostan, M.-M., St\u0103tescu, C., Anghel, L., \u0218erban, I.-L., Cojocaru, E., and Sasc\u0103u, R. (2020). Post-Myocardial Infarction Ventricular Remodeling Biomarkers\u2014The Key Link between Pathophysiology and Clinic. Biomolecules, 10.","DOI":"10.3390\/biom10111587"},{"key":"ref_65","first-page":"A13962","article-title":"Abstract 13962: Precision Pharmacological Treatment for Obstructive Hypertrophic Cardiomyopathy with Mavacamten: One-Year Results From PIONEER-OLE","volume":"140","author":"Heitner","year":"2019","journal-title":"Circulation"},{"key":"ref_66","unstructured":"(2021, March 14). Cytokinetics Announces Progression of REDWOOD-HCM to Cohort 2. Available online: https:\/\/www.globenewswire.com\/news-release\/2020\/12\/09\/2142115\/0\/en\/Cytokinetics-Announces-Progression-of-REDWOOD-HCM-to-Cohort-2.html."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/13\/7218\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:26:08Z","timestamp":1760163968000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/13\/7218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,5]]},"references-count":66,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["ijms22137218"],"URL":"https:\/\/doi.org\/10.3390\/ijms22137218","relation":{},"ISSN":["1422-0067"],"issn-type":[{"type":"electronic","value":"1422-0067"}],"subject":[],"published":{"date-parts":[[2021,7,5]]}}}